Hong Kong

AGBA Group Releases Third Quarter 2023 Financial Results

Retrieved on: 
星期二, 十一月 14, 2023
Acquisition, Security (finance), Coronavirus, Public expenditure, USD, Form 10-Q, Cryptocurrency, Hong Kong

HONG KONG, Nov. 14, 2023 (GLOBE NEWSWIRE) --  NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or “the Company”) the leading one-stop financial supermarket in Hong Kong released its financial results for its third quarter ended September 30, 2023.

Key Points: 
  • HONG KONG, Nov. 14, 2023 (GLOBE NEWSWIRE) --  NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or “the Company”) the leading one-stop financial supermarket in Hong Kong released its financial results for its third quarter ended September 30, 2023.
  • Revenues for the third quarter of 2023 were approximately flat compared to revenues for the third quarter of 2022.
  • During the third quarter of 2023, the company expanded its platform by introducing new products and supporting services for its financial consultants and end-customers.
  • Mr. Wing-Fai Ng, Group President of AGBA Group Holding Limited stated, “We are optimistic that our dedicated efforts will continue to provide momentum to successfully close out 2023 and continue our upward trajectory in 2024.

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
星期二, 十一月 14, 2023
Stargardt disease, Visual acuity, Retina, QEF, Patient, PFIC, Therapy, Conference, Paratriathlon, Grade, Webcast, FAF, Safety, Food, ODD, RPD, Blood, RBP4, Eye, Adolescence, Exercise, Tissue, Vitamin A, University, AMD, DRAGON, Research, Ageing, Disease, FDA, Conference call, Westmead, Geographic atrophy, HIV disease progression rates, Pharmaceutical industry, Fine chemical, Citrus, Security (finance), Cryptocurrency, Stargardt, Hong Kong, PHOENIX, Ophthalmology

ET

Key Points: 
  • ET
    SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the three-months ended September 30, 2023, and provided a general business update.
  • “We made meaningful progress in the quarter advancing our clinical trials for Tinlarebant and are excited by our results,” said Dr. Tom Lin, Chairman and CEO of Belite Bio.
  • Third Quarter 2023 Financial Results:
    Cash: As of September 30, 2023, the Company had $54.5 million in cash.
  • Belite Bio will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.

LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期一, 十一月 13, 2023
ESC, Bristol Myers Squibb, JAMA Cardiology, LIBRA, MITES, Clinical trial, Patient, Demodex, BMS, Congress, European Society of Cardiology, Pharmaceutical industry, Cardiology, Hong Kong

Under the terms of the agreement, LianBio is entitled to receive a total consideration of $350 million.

Key Points: 
  • Under the terms of the agreement, LianBio is entitled to receive a total consideration of $350 million.
  • In July 2023, LianBio entered into a clinical supply agreement with AstraZeneca in China to procure osimertinib for this clinical trial.
  • In October 2023, LianBio announced that the company’s Board of Directors initiated a comprehensive strategic review of the company, with an update anticipated in the first half of 2024.
  • Cash, cash equivalents, marketable securities and restricted cash at September 30, 2023 totaled $252.2 million compared to $302.4 million as of December 31, 2022.

Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results

Retrieved on: 
星期一, 十一月 13, 2023
Longevity, OTCQB, European Medicines Agency, University, Investment, University of Michigan, Clinical trial, EMA, IQVIA, Patient, Regenerative medicine, European, Clinical professor, E-commerce, Greater, LTD, Mayo Clinic, Pharmaceutical industry, Cryptocurrency, Hong Kong

Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced its financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced its financial results for the three and nine months ended September 30, 2023.
  • We activated the second clinical trial site with the University of Michigan in August 2023 to expand the screening of patients.
  • In the third quarter of 2023, the Company’s subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, or HRGN LTD, launched its longevity product business in Asia, generating $40,000 in sales.
  • At September 30, 2023, the Company had operating cash and short-term investments on-hand as of $1.5 million.

Gravity Reports Third Quarter of 2023 Results and Business Updates

Retrieved on: 
星期一, 十一月 13, 2023
Online, Next Generation, Yoy, Federal Reserve Bank, Gravity, International, CBT, Ragnarök, Advertising, Quarter, Pepperstone, KRW, International Accounting Bulletin, International Accounting Standards Board, Ragnarok Online, International Financial Reporting Standards, Cryptocurrency, Video game, Food delivery, Hong Kong

Total revenues were KRW 176,145 million (US$ 130,685 thousand), representing a 26.3% decrease from the second quarter ended June 30, 2023 (“QoQ”) and a 72.1% increase from the third quarter ended September 30, 2022 (“YoY”).

Key Points: 
  • Total revenues were KRW 176,145 million (US$ 130,685 thousand), representing a 26.3% decrease from the second quarter ended June 30, 2023 (“QoQ”) and a 72.1% increase from the third quarter ended September 30, 2022 (“YoY”).
  • Online game revenues for the third quarter of 2023 were KRW 17,316 million (US$ 12,847 thousand), representing an 1.7% increase QoQ from KRW 17,025 million and a 10.1% decrease YoY from KRW 19,271 million.
  • Ragnarok Begins started its second CBT on November 1, 2023 and is preparing to be launched in South Korea in December 2023.
  • The presentation contains the Company’s recent business updates, results of the third quarter in 2023 and Gravity’s business plan.

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Retrieved on: 
星期五, 十一月 10, 2023
Hepatology, Safety, DNA, SAN, Therapy, PEI, HBsAg, AASLD, Emory University, Liver, Week, Doctor of Philosophy, B, CccDNA, Liver cancer, Hepatitis B virus, CHB, Entecavir, MBA, University, Hepatitis, Hong Kong, Physician, Poster, ETV, RNA, Vaccine, Pharmaceutical industry, HBeAg, Boston, New York University, Gastroenterology, Jacob Aligo

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that emerging hepatitis B antigen lowering data for its capsid assembly modulator – empty (CAM-E) drug, ALG-000184, are available as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023.

Key Points: 
  • The data will be presented by Dr. Man-Fung Yuen, Chair and Professor of Gastroenterology and Hepatology at the University of Hong Kong, in Poster Hall C on Monday November 13 from 1-2 pm ET.
  • “ALG-000184 appears to have best-in-class antiviral properties which are also unique compared to other drug classes being evaluated for the treatment of chronic hepatitis B (CHB).
  • If the trends observed to date continue, ALG-000184 has the potential to become a cornerstone therapy in the treatment of CHB.
  • The antiviral effects of ALG-000184 presented at AASLD indicate that this drug is achieving significant viral suppression, likely via inhibition of cccDNA synthesis.

Templeton Emerging Markets Income Fund (“TEI”) Announces Change to Managed Distribution Plan

Retrieved on: 
星期一, 十二月 18, 2023
Asset Management, Professional Services, Finance, NYSE, NAV, Fund, Specialization, International, TEI, Investment, Nationalization, Franklin Templeton Investments, Trustee, Cryptocurrency, Hong Kong

TEMPLETON EMERGING MARKETS INCOME FUND (NYSE: TEI) (the “Fund”), a closed-end investment company managed by Templeton Asset Management Ltd. (“TAML”), announced today that its Board has implemented a new managed distribution plan where the Fund will distribute a level distribution amount to shareholders.

Key Points: 
  • TEMPLETON EMERGING MARKETS INCOME FUND (NYSE: TEI) (the “Fund”), a closed-end investment company managed by Templeton Asset Management Ltd. (“TAML”), announced today that its Board has implemented a new managed distribution plan where the Fund will distribute a level distribution amount to shareholders.
  • The Fund intends to distribute $0.0475 per share monthly which is an annualized distribution rate of 10.10% based on the NAV as of 11/30/2023.
  • The new managed distribution plan will take effect with the distribution that will be payable on January 31, 2024, to shareholders of record on January 19, 2024 (Ex-dividend Date: January 18, 2024).
  • The Board believes that paying a level distribution provides greater consistency to investors and may help how the Fund trades relative to its NAV.

Berkshire Hathaway Specialty Insurance Names Jeff Jubera as Head of Surety Claims

Retrieved on: 
星期一, 十二月 18, 2023
Insurance, Professional Services, Plymouth Meeting, Pennsylvania, General counsel, Standard, AM Best, Health, Berkshire Hathaway, National Indemnity Company, Berkshire Hathaway Travel Protection, Travel, Boston, Hong Kong

Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has promoted Jeff Jubera to Head of Surety Claims.

Key Points: 
  • Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has promoted Jeff Jubera to Head of Surety Claims.
  • “Under Jeff’s management, our claims team has been consistently delivering the best-in-class – CLAIMS IS OUR PRODUCT – claims experience that we strive to provide,” said Robert Romeo, Head of Claims, North America, at BHSI.
  • Prior to BHSI, he was Vice President, Surety Claims, at Intact Insurance Company.
  • Berkshire Hathaway Specialty Insurance ( www.bhspecialty.com ) provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident and health, medical stop loss, homeowners, and multinational insurance.

Wolverine Worldwide Advances Transformation Initiatives

Retrieved on: 
星期一, 十二月 18, 2023
Fashion, Footwear, Retail, Luxury, Other Retail, Specialty, Hush, Annual, NYSE, Wolverine World Wide, Hush Puppies, Exercise, Merrell, Marketing, Keds, Conference, Wolverine, Xtep, Hong Kong, Saucony

Wolverine World Wide, Inc. (“Wolverine Worldwide” or the “Company”) (NYSE: WWW) announced strategic actions that further focus the Company’s portfolio and advance its ongoing transformation into a consumer-obsessed growth company.

Key Points: 
  • Wolverine World Wide, Inc. (“Wolverine Worldwide” or the “Company”) (NYSE: WWW) announced strategic actions that further focus the Company’s portfolio and advance its ongoing transformation into a consumer-obsessed growth company.
  • Wolverine Worldwide formed a joint venture with Xtep in 2019 to launch the Merrell and Saucony brands in China.
  • Wolverine Worldwide has entered into a definitive agreement to sell its Asia-based Wolverine Leathers business to Interhides Public Company Limited, a current materials vendor of the Company, for approximately $9 million.
  • Wolverine will provide more detail regarding these actions and other strategic initiatives at the Annual ICR Conference on January 8, 2024.

 Hult International Business School Marks Successful 2023 with New Academic Programs, Innovation in Higher Education Award

Retrieved on: 
星期五, 十二月 15, 2023
Education, Professional Services, Business, University, Hult, Real-time, Research, International Business School, Fund, Hult International Business School, The Princeton Review, Great Places, Learning, Student, Faculty, International business, Financial Times, Marketing, Doctorate, Curriculum, Growth, Bloomberg Businessweek, Analytics, Management, Tutoring, Boston, Hong Kong

Hult International Business School , a global institution recognized for its challenge-based curriculum and innovative approach to business education, is marking a successful 2023 with significant progress on initiatives important to Hult’s non-profit mission of making an impact that matters.

Key Points: 
  • Hult International Business School , a global institution recognized for its challenge-based curriculum and innovative approach to business education, is marking a successful 2023 with significant progress on initiatives important to Hult’s non-profit mission of making an impact that matters.
  • In addition to introducing several new postgraduate academic programs to prepare students for career success, Hult won the MERIT Award for Innovation in Higher Education for its revised undergraduate program.
  • “This year marked Hult’s 20th anniversary and, fittingly, has been a year of great progress,” said Matt Lilley, President of Hult International Business School.
  • “Our Master's in International Business program now offers domestic and international internship pathways, as well as an accelerated business analytics option.